DXR - Daxor Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
8.02
+0.92 (+12.96%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.10
Open7.16
Bid0.00 x 1000
Ask0.00 x 1300
Day's Range7.15 - 8.69
52 Week Range3.40 - 21.66
Volume1,024,310
Avg. Volume172,458
Market Cap29.904M
Beta (3Y Monthly)-2.86
PE Ratio (TTM)N/A
EPS (TTM)-0.34
Earnings DateN/A
Forward Dividend & Yield0.03 (0.42%)
Ex-Dividend Date2018-01-05
1y Target Est30.00
Trade prices are not sourced from all markets
  • GlobeNewswire19 hours ago

    New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation of Hypertension

    NEW YORK, Nov. 13, 2018 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood.

  • GlobeNewswire6 days ago

    New Data Demonstrating the Clinical Utility of Daxor’s BVA-100 in Hypertension Management to be Presented at the American Heart Association’s Scientific Sessions 2018 

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the American Heart Association Scientific Sessions (AHA) at the McCormick Place Convention Center in Chicago, IL from November 10-12th, 2018. A presentation by Marat Fudim, M.D. of Duke University Medical Center demonstrating the clinical utility of blood volume analysis to help guide hypertension management will be featured.

  • GlobeNewswire7 days ago

    Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Army has selected it for a contract award to develop a blood volume analyzer for improving combat casualty care.

  • GlobeNewswire13 days ago

    CHF Solutions Initiates Strategic Collaboration with Daxor Corporation to Assist in the Management of Patients with Fluid Overload

    CHF Solutions, Inc. (CHFS) announced today that it has entered into a collaboration agreement with Daxor Corporation (DXR) to explore potential synergies between the company’s Aquadex FlexFlow® System and Daxor’s BVA-100 Blood Volume Analyzer.  The company believes that the two technologies can be used together to assess a patient’s fluid volume status and assist in informing on the clinical management of a fluid overloaded patient.

  • GlobeNewswire13 days ago

    Daxor Corporation Initiates Strategic Collaboration with CHF Solutions, Inc. to Manage Patients with Fluid Overload

    DAXOR CORPORATION (NYSE MKT: DXR) announced today that it has entered into an agreement with CHF Solutions (CHFS) to explore clinical synergies between the company’s BVA-100 Blood Volume Analyzer and CHF Solutions’ Aquadex FlexFlow® System to assess the benefit of combining Daxor’s fluid volume diagnostic with Aquadex FlexFlow therapy for the management of the fluid overloaded patient. “Daxor serves the same community of health care providers seeking to improve heart failure outcomes.

  • ACCESSWIRE14 days ago

    Today’s Research Reports on Stocks to Watch: Daxor and Pfizer

    NEW YORK, NY / ACCESSWIRE / October 31, 2018 / Pharmaceutical giant Pfizer was little changed on Tuesday despite mixed earnings and news about price increases on drugs from its CEO Ian Read. Shares of Daxor Corporation were exploding as the company announcing the publication of promising data. Daxor Corporation shares were up nearly 87% on Tuesday on about 5.3 million shares traded.

  • GlobeNewswire15 days ago

    New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients

    Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality NEW YORK , Oct..

  • GlobeNewswire2 months ago

    Daxor Corporation Appoints Robert J. Michel as Chief Financial Officer

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the appointment of Robert J. Michel, CPA, MBA as its new chief financial officer, effective September 28, 2018. “Bob joins Daxor with significant experience across a wide array of industries, including serving on the board of a biometric solutions company . In addition, his public company expertise, combined with his comfort in working and communicating with the investor public make him an important addition to the Daxor team,” commented Michael Feldschuh, CEO of Daxor Corporation.

  • GlobeNewswire2 months ago

    Daxor Corporation to Present at The MicroCap Conference on October 2, 2018

    Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, today announced that Michael Feldschuh, chief executive officer of Daxor, will be a featured presenter at The MicroCap Conference on Tuesday, October 2, 2018 at 4:30 PM ET. Daxor Corporation is an innovative medical instrumentation and biotechnology company.

  • GlobeNewswire2 months ago

    New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo Clinic studies showing that direct blood volume analysis provides doctors with important information to inform treatment, and does so at an advantage over surrogate measurements, including cardiac filling pressure and kidney function. The studies were presented Saturday, September 15, 2018 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Nashville, Tenn. “In each study, we compared blood volume analysis to a surrogate marker to understand the best way to treat heart failure and, in one study, heart failure with accompanying kidney disease.

  • GlobeNewswire2 months ago

    Daxor Corporation to Exhibit at the 22nd Annual Scientific Meeting of the Heart Failure Society of America

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) at the Gaylord Opryland Hotel and Convention Center in Nashville, TN from September 15-17th, 2018. “The HFSA’s Annual Scientific Meeting is a premier event that gathers the best scientific minds focused on heart failure research and outcomes.

  • GlobeNewswire3 months ago

    Daxor Corporation Announces a 23 Percent Rise in BVA-100 Kit Sales in the Area of Cardiology and Filing of Form N-CSR for June 30, 2018

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2018. In reporting its mid-year results, Daxor Corporation has seen important developments in 2018 including a 23 percent rise in kit sales related to the use of its diagnostic device, the BVA-100 blood volume analyzer in the area of cardiology, which was driven by important data showing a substantial benefit using the BVA-100 in a study of 245 patients with hospitalized heart failure, Further, data was presented by investigators at the Mayo Clinic during the 2018 American College of Cardiology annual scientific meeting showing a 56 percent reduction in hospital readmissions and 82 percent reduction in mortality for patients measured on a 30-day basis when the BVA-100 test was used to guide treatment compared to a sampled control group.

  • GlobeNewswire3 months ago

    Newly Published Data Show Daxor Corporation's BVA-100 Is Superior To Formula-Based Estimates of Blood Volume In Assessing Patients With Heart Failure

    Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of an investigator-initiated study from Duke University and The Mayo Clinic demonstrating that despite the widespread use of formula-derived estimates of plasma volume in heart failure patients, these methods are inaccurate compared to measured volume using the company’s BVA-100 blood volume measurement diagnostic. The study, “Calculated Estimates of Plasma Volume in Patients with Chronic Heart Failure – Comparison to Measured Volumes” was recently published in the Journal of Cardiac Failure.

  • ACCESSWIRE5 months ago

    Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

    On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).

  • ACCESSWIRE6 months ago

    Free Daily Technical Summary Reports on Endologix and Three Other Medical Supplies Stocks

    Ahead of today's trading session, WallStEquities.com scans Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Halyard Health Inc. (NYSE: HYH). Companies in the Medical Instruments and Supplies space manufacture and sell medical devices, instrument systems, and reagents and consumables.

  • Are Daxor Corporation’s (NYSEMKT:DXR) Interest Costs Too High?
    Simply Wall St.6 months ago

    Are Daxor Corporation’s (NYSEMKT:DXR) Interest Costs Too High?

    While small-cap stocks, such as Daxor Corporation (AMEX:DXR) with its market cap of US$28.93M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Daxor and Solid Biosciences

    NEW YORK, NY / ACCESSWIRE / March 16, 2018 / Daxor shares were skyrocketing in Thursday trading with gains as high as over 130% after physician-researchers of Mayo Clinic presented new positive findings ...

  • ACCESSWIRE8 months ago

    Daxor, Analysis of the BVA-100 Updates, Financial Data, and Product Review

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...